Saturday 17 October 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
177.96
11.30
−5.97%
Follow RVMD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 4 | 2 | 3 | — | — | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | 7.73 | 7.76 | 7.32 | 13.69 | — | — | — |
P/S ratio |
— | — | 118.70 | 52.30 | 62.35 | 50.54 | 1.60 | 1.60 | — |
Altman Z″-Score (non-manufacturers) |
— | — | 10.28 | 5.56 | 5.67 | 7.24 | 1.08 | (0.20) | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | (4.29) | (2.69) | (2.95) | (3.12) | (1.66) | — | — |
P/Operating CF |
— | — | (26.49) | (29.95) | (46.67) | (86.78) | (6.88) | (6.88) | — |
P/B ratio |
— | — | 1.75 | 2.70 | 3.04 | 4.58 | 0.00 | 0.00 | — |
Price to Tangible BV |
— | — | 1.82 | 3.02 | 3.47 | 5.44 | 0.00 | 0.00 | — |
EV/Sales |
— | — | 51.96 | 35.68 | 44.77 | 40.96 | (0.85) | (0.85) | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.83 | 0.83 | — |
EV/Operating CF |
— | — | (3.99) | (5.63) | (8.94) | (17.60) | 0.86 | 0.86 | — |
EV/FCF |
— | — | (3.90) | (5.37) | (8.56) | (17.09) | 0.93 | 0.93 | — |
Quick Ratio |
6.97 | 13.97 | 12.89 | 10.48 | 9.66 | 9.48 | 3.05 | 2.52 | 1.19 |
Current Ratio |
7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.80 | 1.24 |
Net Debt/EBITDA |
1.47 | 3.17 | 3.71 | 2.33 | 2.91 | 3.99 | 2.40 | 1.80 | 0.30 |
Debt/Assets |
11.40% | 0.00% | 0.00% | 7.07% | 8.19% | 5.11% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.16 | 0.00 | 0.00 | 0.08 | 0.10 | 0.06 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.05 | 0.05 | 0.11 | 0.26 | 0.24 | 0.00 |
Operating CF/Net income |
0.79 | 0.93 | 0.80 | 0.90 | 0.79 | 0.91 | 0.80 | (0.02) | 0.72 |
Capex/Depreciation |
1.42 | 0.31 | 0.60 | (1.64) | (0.63) | (0.39) | 1.25 | (0.85) | (1.33) |
Interest Coverage |
(48.80) | — | (1,607.87) | (28.21) | (15,667.33) | (1,559.11) | (510.57) | (347.66) | (302.22) |
| (58.07%) | (29.33%) | (34.75%) | (38.63%) | (34.74%) | (68.54%) | 47.44% | 55.43% | 39.62% | |
| (46.06%) | (25.98%) | (30.37%) | (32.09%) | (28.66%) | (28.02%) | (31.65%) | (57.24%) | (37.00%) | |
ROIC |
0.00% | 0.00% | 0.00% | (165.26%) | (136.74%) | (109.95%) | (113.59%) | (93.10%) | 0.00% |
Return on Tangible Assets |
(62.23%) | (27.43%) | (24.82%) | (40.32%) | (34.58%) | (26.54%) | (63.12%) | (79.06%) | (491.69%) |
Average Days of Receivables |
— | — | 39.53 | 48.21 | 73.63 | 54.29 | 63.73 | 132.19 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 3,654.09% | 715.30% | 636.09% | 307.68% | 183.36% | 253.33% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 653.03% | 114.71% | 103.61% | 49.85% | 24.79% | 46.67% | 0.00% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.04 | 0.09 | 0.10 | 0.13 | 0.35 | 0.46 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 533.44% | 88.17% | 70.51% | 20.67% | 6.32% | 4.24% | 0.00% |
Graham Net Nets |
— | — | 0.51 | 0.29 | 0.25 | 0.17 | 0.82 | 0.82 | — |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 145.87 | 0.00 | — |
Earnings Yield |
— | — | (13.35%) | (13.51%) | (10.17%) | (5.41%) | (59.48%) | (59.48%) | — |
Free Cash Flow Yield |
— | — | (11.22%) | (12.71%) | (8.39%) | (4.74%) | (57.41%) | (57.41%) | — |
Revenue per Share |
0.00 | 0.00 | 0.10 | 0.44 | 0.40 | 0.78 | 18.05 | 8.77 | 0.00 |
Operating CF per Share |
(4.72) | (3.32) | (3.10) | (2.78) | (2.02) | (1.82) | (17.89) | 0.53 | (14.60) |
Capex per Share |
(0.08) | (0.06) | (0.07) | (0.13) | (0.09) | (0.05) | 1.30 | (0.65) | (0.91) |
Free Cash Flow per Share |
(4.81) | (3.38) | (3.17) | (2.92) | (2.11) | (1.88) | (16.59) | (0.12) | (15.51) |
Cash per Share |
10.65 | 13.65 | 16.38 | 8.00 | 7.93 | 8.03 | 44.27 | 30.27 | 5.27 |
Shareholders Equity per Share |
8.58 | 13.50 | 16.14 | 8.50 | 8.28 | 8.65 | 55.01 | 42.04 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.58 | 13.50 | 16.14 | 8.50 | 8.28 | 8.65 | 55.01 | 42.04 | 0.00 |
Free Cash Flow |
(913.73) | (567.74) | (358.30) | (235.22) | (153.71) | (103.00) | (46.01) | (0.29) | (26.72) |
Working Capital |
1,784.61 | 2,163.72 | 1,735.43 | 598.20 | 529.42 | 406.95 | 90.93 | 54.88 | 1.84 |
Capital Expenditures |
(15.99) | (10.31) | (7.73) | (10.82) | (6.53) | (2.93) | 3.61 | (1.50) | (1.57) |
Net Current Asset Value |
1,351.83 | 2,034.54 | 1,643.77 | 533.44 | 454.35 | 361.40 | 65.99 | 11.50 | 9.44 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.79 | 0.79 | — |
Capex to Sales |
0.00 | 0.00 | 0.67 | 0.31 | 0.22 | 0.07 | (0.07) | 0.07 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.34) | (1.35) | (0.56) | 0.35 | 0.90 | 0.84 | 0.40 | 0.26 | 0.23 |
Cash ROIC |
(23.28%) | (12.47%) | (9.74%) | (16.95%) | (12.40%) | (10.91%) | (16.71%) | (0.17%) | (294.34%) |
Accounts Receivable Turnover |
— | — | 3.91 | 6.67 | 4.77 | 5.68 | 6.24 | 2.51 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Receivables |
— | — | 2.96 | 5.30 | 6.16 | 7.57 | 8.02 | 8.02 | — |
Average Payables |
59.52 | 58.11 | 41.55 | 17.68 | 13.33 | 12.00 | 8.32 | 4.29 | 4.29 |
Average Assets |
2,456.40 | 2,310.00 | 1,436.82 | 774.96 | 652.69 | 393.97 | 195.56 | 85.29 | 94.29 |
Average Common Equity |
1,948.25 | 2,045.70 | 1,255.69 | 643.88 | 538.62 | 161.05 | (130.50) | (88.07) | (88.07) |
Columns are period end dates